Biodesix (BDSX) Competitors $0.45 +0.06 (+14.62%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.40 -0.04 (-9.84%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDSX vs. XGN, DCGO, EUDA, SERA, QIPT, CORBF, ATPC, BNR, PIII, and NAKAShould you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), DocGo (DCGO), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), Agape ATP (ATPC), Burning Rock Biotech (BNR), P3 Health Partners (PIII), and KindlyMD (NAKA). These companies are all part of the "healthcare" industry. Biodesix vs. Its Competitors Exagen DocGo EUDA Health Sera Prognostics Quipt Home Medical Global Cord Blood Agape ATP Burning Rock Biotech P3 Health Partners KindlyMD Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings. Do insiders & institutionals have more ownership in XGN or BDSX? 75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 30.1% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer XGN or BDSX? Exagen presently has a consensus target price of $11.25, indicating a potential upside of 25.14%. Biodesix has a consensus target price of $1.75, indicating a potential upside of 291.50%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Biodesix 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable earnings and valuation, XGN or BDSX? Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$58.86M3.36-$15.11M-$0.89-10.10Biodesix$71.32M0.92-$42.93M-$0.29-1.54 Is XGN or BDSX more profitable? Exagen has a net margin of -28.85% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -130.38% beat Biodesix's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-28.85% -130.38% -34.69% Biodesix -54.28%-167.28%-39.96% Which has more risk and volatility, XGN or BDSX? Exagen has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Does the media favor XGN or BDSX? In the previous week, Exagen had 14 more articles in the media than Biodesix. MarketBeat recorded 18 mentions for Exagen and 4 mentions for Biodesix. Exagen's average media sentiment score of 0.26 beat Biodesix's score of 0.00 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryExagen beats Biodesix on 11 of the 16 factors compared between the two stocks. Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDSX vs. The Competition Export to ExcelMetricBiodesixMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.16M$7.13B$5.48B$9.56BDividend YieldN/A2.83%3.99%4.17%P/E Ratio-1.5462.8629.9325.14Price / Sales0.9226.91375.2276.13Price / CashN/A26.5935.9458.58Price / Book3.1917.548.105.59Net Income-$42.93M$239.96M$3.26B$265.48M7 Day Performance23.07%1.08%0.68%1.22%1 Month Performance52.04%-3.72%2.45%0.39%1 Year Performance-72.74%22.84%27.72%23.47% Biodesix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDSXBiodesix3.7012 of 5 stars$0.45+14.6%$1.75+291.5%-71.9%$57.16M$71.32M-1.54220News CoverageEarnings ReportGap UpHigh Trading VolumeXGNExagen4.5524 of 5 stars$8.85+2.5%$11.25+27.1%+266.9%$189.89M$55.64M-9.94220DCGODocGo2.7475 of 5 stars$1.40+5.3%$3.56+154.3%-53.5%$135.64M$616.55M-70.004,407News CoverageEarnings ReportEUDAEUDA Health1.2231 of 5 stars$3.03-4.1%N/A-26.5%$117.60M$4.01M0.002News CoveragePositive NewsGap DownSERASera Prognostics0.5172 of 5 stars$2.59-4.1%N/A-64.9%$101.72M$80K-2.76120News CoverageEarnings ReportGap DownQIPTQuipt Home Medical2.5236 of 5 stars$2.41+4.3%$2.85+18.3%-35.0%$100.36M$245.91M-11.481,200Upcoming EarningsCORBFGlobal Cord BloodN/A$0.71flatN/A-10.0%$86.30M$196.12M0.001,200Gap UpATPCAgape ATP0.3274 of 5 stars$1.39+3.3%N/A-46.6%$67.31M$1.32M-2.3240Upcoming EarningsBNRBurning Rock Biotech0.8939 of 5 stars$6.15+8.5%N/A-4.4%$61.02M$70.67M-3.251,390Gap UpPIIIP3 Health Partners2.3404 of 5 stars$7.19-2.2%$16.25+126.0%-77.8%$52.83M$1.50B-0.15500Upcoming EarningsGap DownNAKAKindlyMDN/A$7.58+19.4%N/AN/A$46.39M$2.72M-9.84N/AEarnings ReportGap Up Related Companies and Tools Related Companies XGN Competitors DCGO Competitors EUDA Competitors SERA Competitors QIPT Competitors CORBF Competitors ATPC Competitors BNR Competitors PIII Competitors NAKA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDSX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDSX Stock Alerts